News - Kineret (anakinra)

Pathogenic TET2 Variants and Autoinflammatory Manifestations in Myeloid Hematologic Malignancies: Case Report and Literature Review. (PubMed, Eur J Rheumatol)

Despite initial treatment with corticosteroids and diuretics, her condition worsened, which led to the need to implement treatment with colchicine and anakinra. Eur J Rheumatol. 2026, 13(1), 0119, doi:10.5152/eurjrheum.2026.24119.

3 days ago

Journal

TET2 (Tet Methylcytosine Dioxygenase 2)

Kineret (anakinra)

POPS or POP02: Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) (clinicaltrials.gov)

P=N/A, N=5000, Recruiting, Duke University | Trial primary completion date: Sep 2026 --> Mar 2027

4 days ago

Trial primary completion date

dexamethasone • metformin • Actemra IV (tocilizumab) • Ilaris (canakinumab) • Kevzara (sarilumab) • Kineret (anakinra) • Orencia (abatacept) • Valcyte (valganciclovir) • aspirin

Giant Cell Arteritis and Anakinra Trial (clinicaltrials.gov)

P3, N=30, Terminated, University Hospital, Caen | N=70 --> 30 | Unknown status --> Terminated; experimental treatment no longer available

9 days ago

Enrollment change • Trial termination

Kineret (anakinra)

10d

Chimeric antigen receptor T-cell therapies related to immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome: Diagnosis, high-risk factors, and management. (PubMed, Chin Med J (Engl))

For management, we evaluate conventional therapies (corticosteroids, etoposide) and emerging immunomodulatory agents (anakinra, ruxolitinib, emapalumab), emphasizing the 2023 treatment regimen by the American Society of Transplantation and Cellular Therapy (ASTCT). By integrating risk stratification, early diagnostic criteria, and tailored therapeutic approaches, this review aims to improve clinical outcomes for IEC-HS patients.

10 days ago

Journal • IO biomarker

TET2 (Tet Methylcytosine Dioxygenase 2) • IFNG (Interferon, gamma) • CD22 (CD22 Molecule) • CRP (C-reactive protein)

TET2 mutation

Jakafi (ruxolitinib) • etoposide IV • Kineret (anakinra)

10d

ILIPO: "IL-1β Blockade to Prevent Immunothrombosis in Recipients of a Pancreatic Organ" (clinicaltrials.gov)

P1/2, N=15, Not yet recruiting, Nantes University Hospital

10 days ago

New P1/2 trial

Kineret (anakinra)

26d

RC24-0546: IL-1? blockade to prevent Immunothrombosis in recipients of a Pancreatic Organ (ILIPO) (2025-524834-24-00)

P1/2, N=15, Not yet recruiting, Centre Hospitalier Universitaire De Nantes

26 days ago

New P1/2 trial

Kineret (anakinra)

28d

Inflammasome Activation by Neutrophil Extracellular Traps (NETs) in the MDA-MB-231 Human Breast Cancer Cell Line. (PubMed, Int J Mol Sci)

Blocking IL-1R with Anakinra reduced IL1B expression, while inhibition of the P2X7 receptor with A740003 decreased NLRP3 and IL1B...Bioinformatics analysis of TCGA breast cancer samples showed differential inflammasome gene expression among subtypes and a positive correlation between inflammasome components and NET-related genes. These findings highlight the interplay between inflammatory and immune mechanisms in breast cancer progression and may support the development of new therapeutic strategies.

28 days ago

Preclinical • Journal

IL1B (Interleukin 1, beta) • IL1R1 (Interleukin 1 receptor, type I) • NLRP3 (NLR Family Pyrin Domain Containing 3) • CASP1 (Caspase 1)

Kineret (anakinra)

28d

TRIPS: Targeted Reversal of Inflammation in Pediatric Sepsis-induced MODS (clinicaltrials.gov)

P2/3, N=500, Recruiting, Nationwide Children's Hospital | Trial completion date: Aug 2027 --> Aug 2028 | Trial primary completion date: May 2027 --> May 2028

28 days ago

Trial completion date • Trial primary completion date

Kineret (anakinra)

Interleukin-1 receptor type 1 in pancreatic cancer progression and metastasis: a review. (PubMed, Int J Clin Oncol)

Therapeutic blockade of the IL-1 pathway with agents, such as anakinra, canakinumab, or rilonacept, reduces tumor growth, metastasis, and immune suppression in preclinical PDAC models. Summarily, IL-1R1 is a central driver of PDAC aggressiveness and a therapeutic target. Targeting this pathway may enable biomarker-guided strategies to improve outcomes in this disease.

1 month ago

Review • Journal • IO biomarker

MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • STAT3 (Signal Transducer And Activator Of Transcription 3) • IL1B (Interleukin 1, beta) • IL1R1 (Interleukin 1 receptor, type I)

Ilaris (canakinumab) • Kineret (anakinra)

OZM-034: IL-1 Inhibition in Early TNBC (clinicaltrials.gov)

P2, N=0, Withdrawn, University Health Network, Toronto | N=50 --> 0 | Trial completion date: Nov 2027 --> Feb 2026 | Recruiting --> Withdrawn | Trial primary completion date: Nov 2026 --> Feb 2026

1 month ago

Enrollment change • Trial completion date • Trial withdrawal • Trial primary completion date

Kineret (anakinra)

Anakinra in Preventing Severe Chimeric Antigen Receptor T-Cell Related Encephalopathy Syndrome in Patients With Recurrent or Refractory Large B-cell Lymphoma (clinicaltrials.gov)

P2, N=23, Terminated, Jonsson Comprehensive Cancer Center | Trial completion date: Jun 2027 --> Feb 2026 | Active, not recruiting --> Terminated | Trial primary completion date: Jun 2026 --> Feb 2026; slow accrual

1 month ago

Trial completion date • Trial termination • Trial primary completion date

cyclophosphamide • Yescarta (axicabtagene ciloleucel) • fludarabine IV • Kineret (anakinra)

Pilot Study of Atorvastatin and Anakinra in Children With Coronary Artery Abnormalities Secondary to Kawasaki Disease (clinicaltrials.gov)

P1, N=5, Completed, University of California, San Diego | Active, not recruiting --> Completed | N=10 --> 5

1 month ago

Trial completion • Enrollment change

atorvastatin • Kineret (anakinra)